PND2 SAFETY AND IMMUNOGENICITY OF REBIF® NEW FORMULATION (RNF) A NEW SUBCUTANEOUS FORMULATION OF INTERFERON BETA-1A 44 MCG THREE TIMES WEEKLY: 1-YEAR RESULTS OF A PHASE IIIB STUDY IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS

Autor: Simsarian, J, AL-Sabbagh, A, Bennett, R, Stubinski, B, Pardo, G
Zdroj: In Value in Health 2007 10(3):A87-A87
Databáze: ScienceDirect
Externí odkaz: